AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04177719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo will be given intranasally. The order of administration will be counterbalanced
Trial: NCT01358903
Drug: RO5429083
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts receiving multiple escalating doses iv
Trial: NCT01358903
Drug: RO5429083
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
Trial: NCT00395369
Drug: intraoperative aprotinin administration
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02845336
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib 100mg PO twice per day for 3 months
Trial: NCT02590081
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02590081
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00880828
Drug: Acetaminophen only
RxNorm normalized name: Acetaminophen only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen QID/PRN for 4 weeks
Trial: NCT05188911
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients would get medical or surgical castration.
Trial: NCT04248179
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9%
Trial: NCT00959764
Drug: Oral Calcitonin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Calcitonin tablets along with matching placebo intranasal spray
Trial: NCT00959764
Drug: Intranasal Calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Calcitonin Spray
Trial: NCT00959764
Drug: Placebo tablets and placebo intranasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo Tablets/Intranasal placebo spray
Trial: NCT03863249
Drug: ADJUNTIVE ANTIBIOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN.
Trial: NCT03740945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of one placebo vaginal ovule at bedtime
Trial: NCT03740945
Drug: Prasterone (DHEA)
RxNorm normalized name: prasterone (DHEA)
DrugBank: Prasterone sulfate (DB05804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily administration of one prasterone vaginal ovule at bedtime
Trial: NCT01135199
Drug: pomalidomide (CC-4047
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04248179
Drug: Sufentanil and PONV prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV prophylaxis) will be administered.
Trial: NCT00254449
Drug: NGX-4010
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01619774
Drug: GSK2118436
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 150 mg by mouth twice a day.
Trial: NCT01619774
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg by mouth daily.
Trial: NCT02337257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will receive placebo one pill per day for 16 weeks
Trial: NCT03780608
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
Trial: NCT00469183
Drug: Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
Trial: NCT04391127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
Trial: NCT00267384
Drug: Oral N-Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02231723
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered continuously twice daily with doses separated by 12 hours
Trial: NCT02231723
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Trial: NCT02231723
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
Trial: NCT02289417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01988636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01802931
Drug: GSK239512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3 receptor antagonist, potential victim of drug-drug interaction
Trial: NCT05315128
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A randomized comparative effectiveness clinical trial
Trial: NCT03068481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00858780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator once weekly + methotrexate
Trial: NCT01270776
Drug: 2% Chlorhexidine 70% isopropyl alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
Trial: NCT04360915
Drug: ASK120067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take ASK120067 tablets orally in first day at 160 mg in fast condition.
Trial: NCT04133311
Drug: Xalatan®/DE-130A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.
Trial: NCT00313378
Drug: Hypothetica
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03920579
Drug: CKD-386 formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 1 tablet under fasting conditions for each period
Trial: NCT03920579
Drug: D326, D337 and D013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
Trial: NCT03566316
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00645853
Drug: AZD0837
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
Trial: NCT03896594
Drug: HL237
RxNorm normalized name: Hydrocodone/Levorphanol 237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT03896594
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with same properties except for active ingredient
Trial: NCT00408356
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06098313
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)
Trial: NCT01161147
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam Tablets 15 mg
Trial: NCT01691001
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00679302
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
Trial: NCT03440021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical in appearance to experimental drug, not psycho-active
Trial: NCT01566435
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01942135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
Trial: NCT00600483
Drug: gentamicin-collagen sponge dipped in saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-cm2 sponge
Trial: NCT01360086
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
Trial: NCT01360086
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02772822
Drug: SCT400 plus CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03956420
Drug: Preoperative period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
Trial: NCT03956420
Drug: Intraoperative period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
Trial: NCT03956420
Drug: Intraoperative period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 30 mg i.v. after induction of anaesthesia
Trial: NCT03956420
Drug: Intraoperative period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane 1.5 MAC higher in patients \< 60 years old
Trial: NCT03956420
Drug: Intraoperative period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
Trial: NCT03956420
Drug: Intraoperative period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
Trial: NCT00005850
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
Trial: NCT00396162
Drug: probiotic containing L.rhamnosus R0011 strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
Trial: NCT00059332
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
Trial: NCT01481025
Drug: Cimicifuga + Hiperico
RxNorm normalized name: Actaea cimicifuga root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months
Trial: NCT01481025
Drug: Aplause®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
Trial: NCT01162421
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
Trial: NCT04147208
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered RTV 100 mg orally three times daily in fed state
Trial: NCT00766480
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00147199
Drug: Placebo inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses are titrated to 9 breaths four times daily.
Trial: NCT00653822
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and SC
Trial: NCT04162899
Drug: Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
Trial: NCT02333123
Drug: Placebo (for Aspirin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
Trial: NCT04621617
Drug: Standard medical therapy (SMT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
Trial: NCT03002935
Drug: BPM31510 Oral Nanosuspension 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
Trial: NCT01850524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IXAZOMIB matching-placebo capsules.
Trial: NCT00595140
Drug: combination with dopamine agonist cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, 0.5mg, one time
Trial: NCT04327388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Trial: NCT01816581
Drug: Oxynorm
RxNorm normalized name: Oxynorm
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03310970
Drug: Lidoderm 5% patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will wear three Lidoderm® topical patches for 12 hours.
Trial: NCT04352062
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01110200
Drug: ADVAIR DISKUS 250/50 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
Trial: NCT01110200
Drug: SEREVENT 50 mcg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
Trial: NCT02163174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
Trial: NCT01964235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally and continuously on a twice a day dosing schedule.
Trial: NCT00751751
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
Trial: NCT00751751
Drug: losartan + hydrochlorothiazide, if necessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
Trial: NCT00170729
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02754089
Drug: Rhus Coriaria L.(Rhus)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily after meals for 6 weeks
Trial: NCT02754089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily after meals for 6 weeks
Trial: NCT00488176
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03291145
Drug: Beta Blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: With and without Beta Blockers
Trial: NCT03291145
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brisk Standing before and after seven days treatment with Spironolactone
Trial: NCT02586350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo p.o. qd
Trial: NCT01997463
Drug: Supervised asthma therapy in schools
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy observed daily in school. Asthma education by American Lung Association
Trial: NCT01753856
Drug: Demeclocycline
RxNorm normalized name: Demeclocycline
DrugBank: Demeclocycline (DB00618)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01753856
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01753856
Drug: Calcium Supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03694821
Drug: Hylan G-F 20
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One knee injection of Hylan G-F 20 (Synvisc-One)
Trial: NCT01716572
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
Trial: NCT00609596
Drug: GI198745
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01507376
Drug: recombinant hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant hCG(250 µg Ovitrell)
Trial: NCT01507376
Drug: recombinant hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant hCG(500 µg Ovitrell)
Trial: NCT02551276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06350825
Drug: ADT+second-generation antiandrogens ± chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC(Triplet or doublet therapy) for mHSPC
Trial: NCT01557166
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
Trial: NCT05223361
Drug: Six percent hydroxy ethyl starch 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% HES 130/0.4 additive to ringer lactate as prime solution
Trial: NCT05223361
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate as prime solution
Trial: NCT00006465
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
Trial: NCT02180321
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
Trial: NCT02704091
Drug: Smecta
RxNorm normalized name: Umecta
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02704091
Drug: Smecta placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02751905
Drug: BIIB074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as specified in treatment arm
Trial: NCT00563342
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
Trial: NCT03742037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod